U.S. Markets open in 6 mins

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.68-0.27 (-2.47%)
At close: 04:00PM EST
10.68 0.00 (0.00%)
After hours: 04:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.95
Bid8.00 x 1300
Ask0.00 x 900
Day's Range10.54 - 11.10
52 Week Range6.09 - 20.30
Avg. Volume210,284
Market Cap337.953M
Beta (5Y Monthly)0.37
PE Ratio (TTM)N/A
EPS (TTM)-4.00
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.83
  • GlobeNewswire

    Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

    Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total financing potentially available increased to $300 million Commercial launches in H. pylori, and Erosive Esophagitis (EE), if approved, anticipated in Q1 2023 FLORHAM PARK, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Phathom Phar

  • GlobeNewswire

    Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

    FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management team will participate in upcoming investor conferences: Guggenheim Healthcare Talks: 4th Annual Neuro/Immunology Conference Presentation Date: November 14, 2022 Presentation Time: 2:45 PM ET Jefferies London Healthcare Co

  • GlobeNewswire

    Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

    Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital Provides agreement for additional $15 million upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) and $25 million for achievement of a sales milestone FLORHAM PARK, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializ